DOI,title,author,year,times_seen
10.1097/inf.0b013e3182a743c7,Population Pharmacokinetics of Piperacillin/Tazobactam in Critically Ill Young Children,Cies,2013,2
10.1186/s13054-015-1151-y,Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models,Shekar,2015,2
10.1086/668439,Infections Acquired by Adults Who Receive Extracorporeal Membrane Oxygenation Risk Factors and Outcome,Aubron,2012,1
10.1016/j.ijid.2021.05.044,Comparison of piperacillin plasma concentrations in a prospective randomised trial of extended infusion versus intermittent bolus of piperacillin/tazobactam in paediatric patients,Chongcharoenyanon,2021,4
10.1128/aac.48.12.4718-4724.2004,Pharmacodynamic Profiling of Piperacillin in the Presence of Tazobactam in Patients through the Use of Population Pharmacokinetic Models and Monte Carlo Simulation,Lodise,2004,1
10.1592/phco.22.8.569.33209,Pharmacokinetic and Pharmacodynamic Evaluation of Two Dosing Regimens for Piperacillin-Tazobactam,Kim,2004,1
10.5863/1551-6776-19.4.262,Developmental Pharmacokinetics in Pediatric Populations,Lu,2020,6
10.1046/j.1528-1157.43.s.3.5.x,Children Versus Adults: Pharmacokinetic and Adverse-Effect Differences,Anderson,2003,1
10.1111/j.1528-1157.1994.tb02546.x,Severe Hepatotoxicity During Valproate Therapy: An Update and Report of Eight New Fatalities,Konig,2005,1
10.1111/j.1528-1157.1979.tb04853.x,Stupor Following Administration of Valproic Acid to Patients Receiving Other Antiepileptic Drugs,Sackellares,2007,1
10.1016/j.ijantimicag.2016.09.010,Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?,Tran,2016,4
10.1086/516284,State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men,Craig,2007,3
10.2165/00003088-200645080-00001,Antibacterial Dosing in Intensive Care,Roberts,2006,2
10.1128/aac.46.5.1475-1480.2002,Intrapulmonary Pharmacokinetics of Linezolid,Conte,2002,1
10.1128/aac.40.7.1617,"Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects",Conte,2018,1
10.1002/jcph.566,Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumonia,Xiao,2015,3
10.1128/aac.00049-14,"Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections",Lucasti,2014,1
10.1016/j.clinthera.2008.04.019,"Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study",Lucasti,2008,1
10.2165/00003495-200565120-00002,Critical Issues in the Clinical Management of Complicated Intra-Abdominal Infections,Blot,2006,1
10.1097/00075198-200104000-00010,Diagnosis of intra-abdominal infection in the critically ill patient,Evans,2003,1
10.1097/00000658-199607000-00003,Management of Secondary Peritonitis,Wittmann,2003,1
10.1128/cmr.05041-11,Combination Therapy for Treatment of Infections with Gram-Negative Bacteria,Tamma,2012,3
10.1128/aac.25.4.534,In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa,Giamarellou,2012,1
10.1097/ccm.0b013e31816f7cf7,Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock*,Combes,2009,1
10.1016/s0003-4975(00)02620-5,The use of extracorporeal life support in adult patients with primary cardiac failure as a bridge to implantable left ventricular assist device,Pagani,2002,1
10.1097/00002480-199609000-00103,Extracorporeal Life Support for Cardiovascular Support in Adults,KOLLA,2006,1
10.1093/cid/cis545,Does the Piperacillin Minimum Inhibitory Concentration for Pseudomonas aeruginosa Influence Clinical Outcomes of Children With Pseudomonal Bacteremia?,Tamma,2012,2
10.1128/aac.04402-14,Plasma and Epithelial Lining Fluid Pharmacokinetics of Ceftolozane and Tazobactam Alone and in Combination in Mice,Melchers,2015,1
10.1016/j.ijantimicag.2014.04.017,"In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: Comparison with ceftazidime, piperacillin/tazobactam and imipenem",Bretonnière,2014,3
10.1093/jac/dkq143,Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1,Riera,2010,1
10.1093/jac/dkp193,Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum- -lactamase-producing Pseudomonas aeruginosa,Giske,2009,1
10.1128/aac.49.9.3743-3748.2005,"BEL-1, a Novel Clavulanic Acid-Inhibited Extended-Spectrum β-Lactamase, and the Class 1 Integron In120 in
            <i>Pseudomonas aeruginosa</i>",Poirel,2005,1
10.1111/j.1574-6968.2004.tb09535.x,Novel GES/IBC extended-spectrum Î²-lactamase variants with carbapenemase activity in clinical enterobacteria,Vourli,2006,1
10.1128/aac.46.4.1053-1058.2002,"<i>bla</i>
            <sub>VIM-2</sub>
            Cassette-Containing Novel Integrons in Metallo-β-Lactamase-Producing
            <i>Pseudomonas aeruginosa</i>
            and
            <i>Pseudomonas putida</i>
            Isolates Disseminated in a Korean Hospital",Lee,2002,1
10.1128/jcm.33.9.2233-2239.1995,Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing,Tenover,2020,1
10.1186/s13054-017-1856-1,Cefepime-induced neurotoxicity: a systematic review,Payne,2017,4
10.1186/cc8941,Prospective monitoring of cefepime in intensive care unit adult patients,Chapuis,2010,2
10.1055/s-2008-1073024,"The Metabolization of Carbamazepine to CBZ-10,11-Epoxide in Children from the Newborn Age to Adolescence",Korinthenberg,2008,1
10.1128/aac.38.10.2480,Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model,Duffull,2012,1
10.1128/aac.46.2.566-569.2002,"Integron-Located
            <i>oxa-32</i>
            Gene Cassette Encoding an Extended-Spectrum Variant of OXA-2 β-Lactamase from
            <i>Pseudomonas aeruginosa</i>",Poirel,2002,1
10.1128/aac.45.2.447-453.2001,"OXA-28, an Extended-Spectrum Variant of OXA-10 β-Lactamase from
            <i>Pseudomonas aeruginosa</i>
            and Its Plasmid- and Integron-Located Gene",Poirel,2002,1
10.1093/jac/dkt523,"An international, multicentre survey of  -lactam antibiotic therapeutic drug monitoring practice in intensive care units",Wong,2014,2
10.1016/j.ijantimicag.2012.06.022,Quantification of seven β-lactam antibiotics and two β-lactamase inhibitors in human plasma using a validated UPLC-MS/MS method,Carlier,2012,1
10.1002/jssc.200600081,Development of a validated HPLC method for the determination of four penicillin antibiotics in pharmaceuticals and human biological fluids,Samanidou,2006,1
10.1016/s0021-9673(01)89539-x,Precolumn derivatization technique for high-performance liquid chromatographic determination of penicillins with fluorescence detection,Iwaki,2002,1
10.1021/ac00121a066,Liquid chromatographic determination of penicillins by postcolumn degradation with sodium hypochlorite,Haginaka,2005,1
10.1592/phco.30.12.1279,"Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing",Lim,2010,4
10.1016/j.clinthera.2008.01.015,"Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: A prospective, open-label, uncontrolled study",Markou,2008,1
10.1016/j.ijantimicag.2005.10.012,In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units,TIMURKAYNAK,2006,1
10.1111/j.1528-1157.1975.tb04738.x,Sodium Di-N-Propylacetate (DPA) in the Treatment of Epilepsy:A Review,Simon,2007,1
10.1016/0013-4694(58)90068-3,Effects of systemically administered ω-amino and guanidino acids on spontaneous and evoked cortical activity in regions of blood-brain barrier destruction,Purpura,2003,1
10.1016/s0021-9258(19)50930-9,IDENTIFICATION OF γ-AMINOBUTYRIC ACID IN BRAIN BY THE ISOTOPE DERIVATIVE METHOD,Udenfriend,2021,1
10.1021/ja01158a027,Determination of Organic Compounds as Isotopic Derivatives.<sup>1</sup> II. Amino Acids by Paper Chomatographic and Indicator Techniques<sup>2</sup>,Keston,2005,1
10.1128/aac.05005-11,Pharmacodynamics of β-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of β-Lactamases,Louie,2011,1
10.1128/aac.31.7.1054,Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance,Blaser,2012,2
10.1111/j.1528-1157.1979.tb04779.x,Valproic Acid Binding to Human Serum Albumin and Determination of Free Fraction in the Presence of Anticonvulsants and Free Fatty Acids,Patel,2007,1
10.1016/s0022-2275(20)39568-7,Kinetic analysis of the oxidation of palmitate-1-14C in man during prolonged heavy muscular exercise,Havel,2021,1
10.1152/ajplegacy.1959.196.2.238,Complete solution of the three-compartment model in steady state after single injection of radioactive tracer,Skinner,2017,1
10.1097/pcc.0000000000002198,Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children,Weiss,2020,3
10.1001/jama.2018.12179,Antibiotics for Sepsis—Finding the Equilibrium,Klompas,2018,1
10.1186/s13054-015-1035-1,Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study,Klein Klouwenberg,2015,1
10.1164/rccm.201307-1376oc,Electronic Implementation of a Novel Surveillance Paradigm for Ventilator-associated Events. Feasibility and Validation,Klein Klouwenberg,2014,1
10.1097/ccm.0b013e31822d7913,A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians criteria*,Skrupky,2011,1
10.1086/587103,Risk of Misleading Ventilator‐Associated Pneumonia Rates with Use of Standard Clinical and Microbiological Criteria,Klompas,2008,1
10.1097/01.ccm.0000181731.53912.d9,Clinical and economic consequences of ventilator-associated pneumonia: A systematic review,Safdar,2005,1
10.1164/ajrccm.152.6.8520743,"The role of intragastric acidity and stress ulcus prophylaxis on colonization and infection in mechanically ventilated ICU patients. A stratified, randomized, double-blind study of sucralfate versus antacids.",Bonten,2013,1
10.1093/qjmed/77.3.1229,Valproate Metabolism During Hepatotoxicity Associated with the Drug,EADIE,2012,1
10.1093/infdis/jiaa118,Optimizing Pharmacokinetics-Pharmacodynamics of Antimicrobial Management in Patients with Sepsis: A Review,Phe,2020,2
10.1097/ccm.0b013e3181a0054d,A systematic review on clinical benefits of continuous administration of β-lactam antibiotics*,Roberts,2009,1
10.1016/j.patbio.2005.06.002,Intérêt pharmacodynamique de la perfusion continue vs l'administration intermittente de ceftazidime dans les pneumonies nosocomiales sévères,Cousson,2005,1
10.2165/00003088-199528020-00005,The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to Outcome,Hyatt,2009,1
10.1093/infdis/158.4.831,Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model,Vogelman,2011,1
10.1186/s13054-018-2217-4,"Ascorbic acid, corticosteroids, and thiamine in sepsis: a review of the biologic rationale and the present state of clinical evaluation",Moskowitz,2018,1
10.1097/ccm.0b013e3181961bff,Pharmacokinetic issues for antibiotics in the critically ill patient,Roberts,2009,4
10.1097/01.ccm.0000098031.24329.10,Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis*,Garnacho-Montero,2003,1
10.1007/bf01709273,Polymicrobial bacteremia in critically ill patients,Rello,2005,1
10.1097/00000441-198009000-00002,Polymicrobial Sepsis: An Analysis of 184 Cases Using Log Linear Models,Mackowiak,2006,1
10.1016/s0022-3476(78)80508-3,Polymicrobial bacteremia associated with pharyngotonsillitis,Rosenfeld,2007,1
10.1093/jac/dkx121,Pharmacodynamics of dose-escalated ‘front-loading’ polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli,Smith,2017,1
10.1128/aac.01267-16,"Detection of
            <i>mcr-1</i>
            among Escherichia coli Clinical Isolates Collected Worldwide as Part of the SENTRY Antimicrobial Surveillance Program in 2014 and 2015",Castanheira,2016,1
10.1016/s1473-3099(15)00424-7,Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study,Liu,2015,2
10.1128/aac.02155-12,"Genetic Characterization of IncI2 Plasmids Carrying
            <i>bla</i>
            <sub>CTX-M-55</sub>
            Spreading in both Pets and Food Animals in China",Lv,2013,1
10.1016/j.mimet.2005.03.018,Identification of plasmids by PCR-based replicon typing,Carattoli,2005,1
10.1007/bf00286181,The region essential for efficient autonomous replication of pSa in Escherichia coli,Okumura,2004,1
10.1073/pnas.82.18.6090,Protein RepC is involved in copy number control of the broad host range plasmid RSF1010.,Haring,2006,1
10.1093/cid/ciw839,Dosing guidance for intravenous colistin in critically-ill patients,Nation,2016,3
10.1161/01.cir.95.7.1844,Bridge Experience With Long-term Implantable Left Ventricular Assist Devices,Oz,2012,1
10.1001/jama.1986.03370140090030,Donor Availability as the Primary Determinant of the Future of Heart Transplantation,Evans,2011,1
10.1002/jcph.1128,Optimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs,Le,2018,3
10.1038/pr.2015.119,The ontogeny of P-glycoprotein in the developing human blood–brain barrier: implication for opioid toxicity in neonates,Lam,2015,1
10.1007/s40262-018-0682-1,Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal Clearance,Béranger,2018,3
10.1097/pcc.0000000000001228,Augmented Renal Clearance Using Population-Based Pharmacokinetic Modeling in Critically Ill Pediatric Patients*,Avedissian,2017,1
10.3109/08880018.2013.810317,"Cystatin C, Beta2 Microglobulin, N-Acetyl-beta-D-glucosaminidase, Retinol-Binding Protein, and Endothelin 1 Levels in the Evaluation of Sickle Cell Disease Nephropathy",Unal,2013,1
10.2215/cjn.00740110,Urinary Biomarkers in the Clinical Prognosis and Early Detection of Acute Kidney Injury,Koyner,2010,1
10.2215/cjn.02860608,Diagnostic Value of Urine Microscopy for Differential Diagnosis of Acute Kidney Injury in Hospitalized Patients,Perazella,2008,1
10.1592/phco.26.9.1320,Application of Antimicrobial Pharmacodynamic Concepts into Clinical Practice: Focus on β-Lactam Antibiotics: Insights from the Society of Infectious Diseases Pharmacists,Lodise,2006,4
10.1128/aac.43.3.623,Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria,Kashuba,2018,2
10.1093/jac/dkg468,Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis,Li,2003,1
10.1128/aac.49.8.3382-3386.2005,"Hypermutation Is a Key Factor in Development of Multiple-Antimicrobial Resistance in
            <i>Pseudomonas aeruginosa</i>
            Strains Causing Chronic Lung Infections",Maciá,2005,1
10.1016/s1368-7646(03)00041-4,The role of mutators in the emergence of antibiotic-resistant bacteria,Chopra,2003,1
10.1093/genetics/162.3.1055,Enrichment and Elimination of <i>mutY</i> Mutators in <i>Escherichia coli</i> Populations,Notley-McRobb,2021,1
10.1093/genetics/152.2.485,"Mutators, Population Size, Adaptive Landscape and the Adaptation of Asexual Populations of Bacteria",Tenaillon,2021,1
10.1146/annurev.mi.40.100186.002055,In Situ Bacterial Metabolism and Colon Mutagens,Goldin,2003,1
10.1128/aac.02831-15,Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii,Tsuji,2016,2
10.1016/s1473-3099(11)70059-7,Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study,Walsh,2011,1
10.1099/mic.0.28255-0,"Subcellular localization and functional domains of the coupling protein, TraG, from IncHI1 plasmid R27",Gunton,2005,1
10.1016/s0966-842x(00)01792-3,Bacterial type IV secretion: conjugation systems adapted to deliver effector molecules to host cells,Christie,2002,1
10.1073/pnas.120156997,"Transferred DNA (T-DNA)-associated proteins of
            <i>Agrobacterium tumefaciens</i>
            are exported independently of
            <i>virB</i>",Chen,2002,1
10.1128/jb.179.10.3085-3094.1997,Agrobacterium tumefaciens T-complex transport apparatus: a paradigm for a new family of multifunctional transporters in eubacteria,Christie,2016,1
10.1073/pnas.93.25.14648,"<i>cag</i>
            , a pathogenicity island of
            <i>Helicobacter pylori,</i>
            encodes type I-specific and disease-associated virulence factors",Censini,2002,1
10.1093/nar/22.22.4756,Intrinsic and extrinsic approaches for detecting genes in a bacterial genome,Borodovsky,2007,1
10.1016/j.jchromb.2004.09.018,Simultaneous determination of amoxicillin and clavulanic acid in human plasma by HPLC–ESI mass spectrometry,YOON,2004,1
10.1001/archsurg.1983.01390030017003,Prognosis in Generalized Peritonitis,Bohnen,2011,1
10.1016/s1473-3099(17)30615-1,Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials,Vardakas,2017,2
10.1002/14651858.cd008481.pub2,Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections,Shiu,2013,1
10.5414/cpp43360,Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen,Georges,2011,1
10.1128/aac.01885-13,Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid,Boak,2014,1
10.1128/aac.49.12.5024-5032.2005,In Vitro Activity of Linezolid against Key Gram-Positive Organisms Isolated in the United States: Results of the LEADER 2004 Surveillance Program,Draghi,2005,1
10.7326/0003-4819-138-2-200301210-00015,Linezolid: The First Oxazolidinone Antimicrobial,Moellering,2013,1
10.5863/1551-6776-22.4.276,Population Pharmacokinetics and Pharmacodynamic Target Attainment of Meropenem in Critically Ill Young Children,Cies,2017,3
10.1086/514622,The Pharmacodynamics of β‐Lactams,Turnidge,2007,2
10.1111/j.1365-2125.2004.02225.x,Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs,Bjorkman,2005,1
10.1097/ccm.0b013e318180fe62,Antibiotic resistance—What’s dosing got to do with it?,Roberts,2009,1
10.1093/jac/dkl135,Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration,Olofsson,2006,1
10.1093/cid/ciu027,DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current  -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?,Roberts,2014,5
10.1177/0310057x9302100206,Aminoglycoside Volume of Distribution and Illness Severity in Critically Ill Septic Patients,Marik,2019,1
10.1097/00007691-198503000-00003,An Overview of Amikacin,Ristuccia,2006,1
10.1016/j.coph.2017.09.004,In vivo infection models in the pre-clinical pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents,Andes,2017,3
10.1128/aac.03572-14,"Impact of MIC Range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the Ceftolozane
            <i>In Vivo</i>
            Pharmacokinetic/Pharmacodynamic Target",Lepak,2014,1
10.1128/aac.06349-11,Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses,Miller,2012,1
10.1086/595011,"Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America",Boucher,2008,2
10.1097/pcc.0000000000001497,Ceftaroline for Suspected or Confirmed Invasive Methicillin-Resistant Staphylococcus aureus,Cies,2018,2
10.1097/mcc.0000000000000235,New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections,Bassetti,2015,2
10.1056/nejmoa1406617,Lower versus Higher Hemoglobin Threshold for Transfusion in Septic Shock,Holst,2014,1
10.1097/ccm.0b013e3181844677,Efficacy of red blood cell transfusion in the critically ill: A systematic review of the literature*,Marik,2008,1
10.1097/01.ccm.0000114810.30477.c3,Red blood cell transfusion and ventilator-associated pneumonia: A potential link?,Shorr,2004,1
10.1001/jama.289.15.1941,Clinical Outcomes Following Institution of the Canadian Universal Leukoreduction Program for Red Blood Cell Transfusions,Hébert,2003,1
10.1128/aac.00654-17,Neurotoxic Concentration of Piperacillin during Continuous Infusion in Critically Ill Patients,Quinton,2017,4
10.1128/aac.00430-09,"Population Pharmacokinetics of Ceftazidime in Intensive Care Unit Patients: Influence of Glomerular Filtration Rate, Mechanical Ventilation, and Reason for Admission",Georges,2009,3
10.1111/j.1365-2125.2000.00179.x,"Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion <i>vs</i>
 intermittent bolus injection in septicaemic melioidosis",Angus,2009,2
10.1002/j.1875-9114.1985.tb03424.x,"Antimicrobial Activity, Pharmacokinetics, Therapeutic Indications and Adverse Reactions of Ceftazidime",Gentry,2015,1
10.1093/jac/8.suppl_b.119,Comparative in-vitro activity of cefsulodin and ceftazidime against ticarcillin-resistant Pseudomonas aeruginosa,Philippon,2012,1
10.1128/aac.01480-13,"<i>In Vivo</i>
            Emergence of Colistin Resistance in Klebsiella pneumoniae Producing KPC-Type Carbapenemases Mediated by Insertional Inactivation of the PhoQ/PhoP
            <i>mgrB</i>
            Regulator",Cannatelli,2013,1
10.1007/s12223-011-0057-6,KPC-2-producing Klebsiella pneumoniae isolated from a Czech patient previously hospitalized in Greece and in vivo selection of colistin resistance,Hrabák,2011,1
10.2807/ese.14.40.19349-en,"First isolations of KPC-2-carrying ST258 Klebsiella pneumoniae strains in Finland, June and August 2009",Österblad,2021,1
10.1128/aac.00881-09,"Attenuation of Colistin Bactericidal Activity by High Inoculum of
            <i>Pseudomonas aeruginosa</i>
            Characterized by a New Mechanism-Based Population Pharmacodynamic Model",Bulitta,2010,2
10.1016/j.ijantimicag.2004.10.001,Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria,Li,2004,1
10.1016/s0021-9673(01)85266-3,Thin-layer chromatographic method for the identification of the polymyxins,Thomas,2002,1
10.1016/s0021-9673(00)99995-3,Improved high-performance liquid chromatographic method for polypeptide antibiotics and its application to study the effects of treatments to reduce microbial levels in bacitracin powder,Tsuji,2002,1
10.1016/s0021-9673(00)90888-4,"Quantitative high-pressure liquid chromatographic analysis of bacitracin, a polypeptide antibiotic",Tsuji,2002,1
10.1016/0003-2697(74)90437-0,Separation of proteins by high-speed pressure liquid chromatography,Shechter,2004,1
10.1093/cid/ciz1155,Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase–4 and New Delhi Metallo-β-Lactamase–1,Yasmin,2019,2
10.1016/j.bmcl.2007.06.089,A minimalistic approach to identify substrate binding features in B1 Metallo-β-lactamases,Poeylaut-Palena,2007,1
10.1128/aac.45.3.660-663.2001,Standard Numbering Scheme for Class B β-Lactamases,Galleni,2002,1
10.1016/j.cmi.2015.06.007,Use of old antibiotics now and in the future from a pharmacokinetic/pharmacodynamic perspective,Muller,2015,3
10.1136/archdischild-2014-307297,Reducing hospital-acquired infections and improving the rational use of antibiotics in a developing country: an effectiveness study,Murni,2014,1
10.1177/1757177411402864,Hand hygiene and transmission of <i>Pseudomonas aeruginosa</i> on hands in a hospital environment,Jones,2011,1
10.1016/j.ejps.2021.105868,Population pharmacokinetics-pharmacodynamics of ceftazidime in neonates and young infants: Dosing optimization for neonatal sepsis,Li,2021,2
10.1086/344653,Prevention of Resistance: A Goal for Dose Selection for Antimicrobial Agents,Drusano,2003,1
10.1001/archinte.1989.00390100083020,Evaluation of Intravenous Ciprofloxacin in Patients With Nosocomial Lower Respiratory Tract Infections,Peloquin,2011,1
10.1016/j.bmc.2016.11.008,Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents,Zhao,2016,1
10.1128/aac.31.11.1803,Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis,Michéa-Hamzehpour,2012,1
10.1038/42701,Evolution of high mutation rates in experimental populations of E. coli,Sniegowski,2002,1
10.1093/genetics/137.4.1139,Fluctuation tests: how reliable are the estimates of mutation rates?,Stewart,2021,1
10.1001/archinte.1971.00310130124022,Factors Affecting Mortality of Gram-Negative Rod Bacteremia,Bryant,2011,1
10.3181/00379727-97-23740,Synaptic Effects of Systemic  -Amino Butyric Acid in Cortical Regions of Increased Vascular Permeability,Purpura,2013,1
10.1136/archdischild-2019-317342,Serum amoxicillin levels in young infants (0–59 days) with sepsis treated with oral amoxicillin,Mir,2020,3
10.1128/aac.45.11.3029-3036.2001,Development and Validation of Limited-Sampling Strategies for Predicting Amoxicillin Pharmacokinetic and Pharmacodynamic Parameters,Suarez-Kurtz,2002,1
10.1002/bmc.1130070407,Simple analysis of amoxycillin in plasma by high performance liquid chromatography with internal standardization and ultraviolet detection,Charles,2005,1
10.1128/aac.22.5.753,"Assay of amoxicillin and clavulanic acid, the components of Augmentin, in biological fluids with high-performance liquid chromatography",Foulstone,2012,1
10.1152/ajplegacy.1959.197.1.34,Effects of cold acclimation on hepatic carbohydrate and lipid metabolism,Felts,2017,1
10.1128/aac.49.8.3593-3597.2005,"Integron-Encoded GES-Type Extended-Spectrum β-Lactamase with Increased Activity toward Aztreonam in
            <i>Pseudomonas aeruginosa</i>",Poirel,2005,1
10.1042/bj2760269,A standard numbering scheme for the class A <i>β</i>-lactamases,Ambler,2015,1
10.1592/phco.23.3.291.32110,"Integration of Population Pharmacokinetics, a Pharmacodynamic Target, and Microbiologic Surveillance Data to Generate a Rational Empiric Dosing Strategy for Cefepime against<i>Pseudomonas aeruginosa</i>",Tam,2004,1
10.1128/aac.45.1.13-22.2001,Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint,Drusano,2002,2
10.1093/infdis/149.1.23,Risk Factors for the Development of Auditory Toxicity in Patients Receiving Aminoglycosides,Moore,2011,1
10.1345/aph.1g467,Meropenem by Continuous Versus Intermittent Infusion in Ventilator-Associated Pneumonia due to Gram-Negative Bacilli,Lorente,2006,1
10.1159/000180580,Prediction of Creatinine Clearance from Serum Creatinine,Cockcroft,2008,2
10.1128/aac.00053-14,Intrapulmonary Posaconazole Penetration at the Infection Site in an Immunosuppressed Murine Model of Invasive Pulmonary Aspergillosis Receiving Oral Prophylactic Regimens,Seyedmousavi,2014,1
10.1164/ajrccm/147.1.148,Bronchoalveolar Lavage: Quantitation of Intraalveolar Fluid?,von Wichert,2011,1
10.1016/0034-5687(78)90104-4,The normal human lung: ultrastructure and morphometric estimation of diffusion capacity,Gehr,2003,1
10.1152/jappl.1967.23.5.694,Vertical gradient of alveolar size in lungs of dogs frozen intact.,Glazier,2017,1
10.1093/cid/cit334,Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens,Sandri,2013,1
10.1016/s1473-3099(06)70580-1,Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections,Li,2006,1
10.1016/s0732-8893(01)00258-9,Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii,Giamarellos-Bourboulis,2002,1
10.1128/aac.44.8.2211-2213.2000,"Comparative Activities of Ciprofloxacin, Clinafloxacin, Gatifloxacin, Gemifloxacin, Levofloxacin, Moxifloxacin, and Trovafloxacin against Epidemiologically Defined
            <i>Acinetobacter baumannii</i>
            Strains",Heinemann,2002,1
10.1128/jcm.33.5.1402-1407.1995,Comparison of ribotyping and pulsed-field gel electrophoresis for molecular typing of Acinetobacter isolates,Seifert,2020,1
10.5863/1551-6776-22.6.467,Therapeutic Drug Monitoring of Prolonged Infusion Aztreonam for Multi-Drug Resistant Pseudomonas aeruginosa: A Case Report,Cies,2017,1
10.1097/ccm.0000000000002817,β-lactam Therapeutic Drug Management in the PICU*,Cies,2017,1
10.1183/09031936.00149508,Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia,Scaglione,2009,1
10.1128/aac.41.10.2188,"OXA-18, a class D clavulanic acid-inhibited extended-spectrum beta-lactamase from Pseudomonas aeruginosa",Philippon,2018,2
10.1186/2110-5820-2-35,Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review,Sime,2012,1
10.1177/00912700122010384,Single-Dose Gabapentin Pharmacokinetics and Safety in Healthy Infants and Children,Haig,2003,1
10.1016/0920-1211(93)90023-z,Gabapentin actions on ligand- and voltage-gated responses in cultured rodent neurons,Rock,2003,1
10.1136/jnnp.50.6.682,Gabapentin as an antiepileptic drug in man.,Crawford,2008,1
10.1111/j.1365-2125.1980.tb01745.x,Psychomotor function and psychoactive drugs.,Hindmarch,2012,3
10.1007/bf00421809,Stimulant and depressant drugs on kinaesthetic figural after-effects,Gupta,2004,1
10.1192/bjp.106.444.852,Drugs and Personality,Eysenck,2008,1
10.1192/bjp.106.444.845,Drugs and Personality,Eysenck,2008,1
10.1037/h0048155,The duration and course of the reaction decrement and the influence of reward.,Walker,2006,1
10.1016/s0732-8893(97)00234-4,Antimicrobial Activity and Spectrum Investigation of Eight Broad-Spectrum β-Lactam Drugs: A 1997 Surveillance Trial in 102 Medical Centers in the United States,Jones,2002,1
10.1093/jac/33.1.137,"In-vitro activity of FK-037, a new parenteral cephalosporin",Jones,2007,1
10.1086/594120,Impact of Enhanced Infection Control at 2 Neonatal Intensive Care Units in The Philippines,Gill,2008,1
10.1016/s0140-6736(05)71881-x,Hospital-acquired neonatal infections in developing countries,Zaidi,2005,1
10.1093/tropej/46.4.237,"Brief report. Neonatal meningitis: mortality, cerebrospinal fluid, and microbiological findings",Nel,2004,1
10.1128/aac.00133-06,Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid,Kiem,2007,1
10.1128/aac.37.5.1073,Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients,Forrest,2012,2
10.1002/cpt.748,Population Pharmacokinetics of Amoxicillin in Term Neonates Undergoing Moderate Hypothermia,Bijleveld,2017,1
10.1136/bmj.c363,Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data,Edwards,2010,1
10.1042/bj3300581,Catalytic properties of class A β-lactamases: efficiency and diversity,MATAGNE,2015,1
10.1128/aac.01590-12,"<i>In Vivo</i>
            Activities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice",Craig,2012,2
10.1016/0732-8893(95)00053-d,Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins,Craig,2002,1
10.1128/aac.26.5.678,Postantibiotic effect of imipenem on Pseudomonas aeruginosa,Bustamante,2012,1
10.1016/j.jhin.2009.11.020,"Prevalence of nosocomial infections in The Netherlands, 2007–2008: results of the first four national studies",van der Kooi,2010,1
10.1016/j.jhin.2007.11.005,Additional direct medical costs of nosocomial infections: an estimation from a cohort of patients in a French university hospital,Defez,2008,1
10.1086/502033,"The Impact of Surgical-Site Infections Following Orthopedic Surgery at a Community Hospital and a University Hospital Adverse Quality of Life, Excess Length of Stay, and Extra Cost",Whitehouse,2006,1
10.1002/art.1780280513,Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research,Liang,2007,1
10.1002/art.1780240113,Measuring functional ability in chronic arthritis. a critical review,H Liang,2007,1
10.1093/jac/dkw355,High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in<i>Acinetobacter baumannii</i>,Lenhard,2016,1
10.1093/jac/15.suppl_a.125,In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives,Blaser,2012,1
10.1093/jac/dkw293,"Polymyxin B in combination with doripenem against heteroresistant
            <i>Acinetobacter baumannii</i>
            : pharmacodynamics of new dosing strategies",Rao,2016,3
10.1128/aac.05298-11,Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic Model,Bergen,2011,2
10.1128/aac.33.10.1724,Fatty acid alterations and polymyxin B binding by lipopolysaccharides from Pseudomonas aeruginosa adapted to polymyxin B resistance,Conrad,2012,1
10.1038/srep26233,Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens,Cheah,2016,3
10.1093/cid/ciu213,"Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?",Nation,2014,1
10.1128/aac.49.9.3624-3630.2005,"Pharmacodynamics of Polymyxin B against
            <i>Pseudomonas aeruginosa</i>",Tam,2005,3
10.1128/jcm.34.5.1129-1135.1996,Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis,Mahenthiralingam,2020,1
10.1128/jb.181.16.4790-4797.1999,The Avr (Effector) Proteins HrmA (HopPsyA) and AvrPto Are Secreted in Culture from Pseudomonas syringaePathovars via the Hrp (Type III) Protein Secretion System in a Temperature- and pH-Sensitive Manner,van Dijk,2019,1
10.1128/jb.179.12.3866-3874.1997,Altered localization of HrpZ in Pseudomonas syringae pv. syringae hrp mutants suggests that different components of the type III secretion pathway control protein translocation across the inner and outer membranes of gram-negative bacteria,Charkowski,2016,1
10.1111/j.1365-2958.1995.tb02284.x,"The hrp gene locus of Pseudomonas solanacearum, which controls the production of a type III secretion system, encodes eight proteins related to components of the bacterial flagellar biogenesis complex",Gijsegem,2006,1
10.1007/bf00283883,A superfamily of proteins involved in different secretion pathways in gram-negative bacteria: modular structure and specificity of the N-terminal domain,Genin,2004,1
10.1128/jb.173.16.4994-5009.1991,"Analysis of virC, an operon involved in the secretion of Yop proteins by Yersinia enterocolitica",Michiels,2016,1
10.1016/0092-8674(90)90378-r,The role of charged amino acids in the localization of secreted and membrane proteins,Boyd,2004,1
10.1016/s0021-9258(19)47220-7,Illicit secretion of a cytoplasmic protein into the periplasm of Escherichia coli requires a signal peptide plus a portion of the cognate secreted protein,Summers,2021,1
10.1073/pnas.74.12.5463,DNA sequencing with chain-terminating inhibitors,Sanger,2006,1
10.1111/j.1365-2958.1991.tb01907.x,Filnmentous phage assembly,Russel,2006,1
10.1128/jvi.42.3.1099-1107.1982,Minor coat protein composition and location of the A protein in bacteriophage f1 spheroids and I-forms,Lopez,2020,1
10.1177/0091270006291035,Population Pharmacokinetic Analysis and Dosing Regimen Optimization of Meropenem in Adult Patients,Li,2006,1
10.1128/aac.00483-18,Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm,Lakota,2018,1
10.1345/aph.1h353,Polymyxin B and Doxycycline Use in Patients with Multidrug-Resistant Acinetobacter baumannii Infections in the Intensive Care Unit,Holloway,2006,1
10.1016/s0140-6736(94)90694-7,Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam,Go,2003,1
10.1097/pcc.0000000000000225,Pediatric Severe Sepsis in U.S. Children’s Hospitals*,Balamuth,2014,3
10.1128/aac.04099-14,Two Mechanisms of Killing of Pseudomonas aeruginosa by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling,Bulitta,2015,2
10.1038/nrd2201,Drugs for bad bugs: confronting the challenges of antibacterial discovery,Payne,2006,1
10.1021/ci0200467,"Property Distributions:  Differences between Drugs, Natural Products, and Molecules from Combinatorial Chemistry",Feher,2003,1
10.1021/ci0003303,Distinguishing between Natural Products and Synthetic Molecules by Descriptor Shannon Entropy Analysis and Binary QSAR Calculations,Stahura,2002,1
10.1021/ci00008a012,Applications of the radius-diameter diagram to the classification of topological and geometrical shapes of chemical compounds,Petitjean,2005,1
10.1111/j.1365-2958.1994.tb00450.x,The Salmonella typhimurium invasion genes invF and invG encode homologues of the AraC and PulD family of proteins,Kaniga,2006,1
10.1016/0378-1119(84)90022-2,The pIC plasmid and phage vectors with versatile cloning sites for recombinant selection by insertional inactivation,Marsh,2003,1
10.1016/0076-6879(83)01005-8,[2] New M13 vectors for cloning,Messing,2004,1
10.1093/nar/9.1.213-c,Restriction and modification enzymes and their recognition sequences,Roberts,2007,1
10.1186/s13054-019-2378-9,Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique—SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d’Anesthésie et Réanimation—SFAR),Guilhaumou,2019,2
10.1186/s13613-015-0093-5,Renal replacement therapy in adult and pediatric intensive care,Vinsonneau,2015,1
10.1128/aac.01368-15,Augmented Renal Clearance Implies a Need for Increased Amoxicillin-Clavulanic Acid Dosing in Critically Ill Children,De Cock,2015,2
10.2165/00003088-200544120-00009,Cystatin C as a New Covariate to Predict Renal Elimination of Drugs,Thomas,2006,1
10.1038/ki.1995.40,Serum cystatin C measured by automated immunoassay: A more sensitive marker of changes in GFR than serum creatinine,Newman,2007,1
10.3109/00365517209084290,A Simple Method for the Determination of Glomerular Filtration Rate,Bröchner-Mortensen,2007,1
10.3109/00365516909081695,Renal Inulin Clearance versus Total Plasma Clearance of<sup>51</sup>Cr-EDTA,Bröchner-mortensen,2007,1
10.1016/s0140-6736(68)91580-8,COMPARISON BETWEEN INULIN AND 51Cr-LABELLED EDETIC ACID FOR THE MEASUREMENT OF GLOMERULAR FILTRATION-RATE,Heath,2004,2
10.3181/00379727-97-23806,Effect of Ethylenediaminetetraacetic Acid on Radiostrontium Excretion in Man.,Spencer,2013,1
10.1128/aac.48.6.1941-1947.2004,"Determination of the In Vivo Pharmacodynamic Profile of Cefepime against Extended-Spectrum-Beta-Lactamase-Producing
            <i>Escherichia coli</i>
            at Various Inocula",Maglio,2004,1
10.1300/j100v05n02_05,Clinical Efficacy of Cefephime in Pneumonia Caused by Pseudomonas aeruginosa,Grant,2003,1
10.1592/phco.19.18.1392.30900,Comparison of Five β-Lactam Antibiotics Against Common Nosocomial Pathogens Using the Time Above MIC at Different Creatinine Clearances,Kays,2004,1
10.1016/0732-8893(95)00019-7,Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers a reevaluation after five years,Marshall,2002,1
10.1016/0732-8893(89)90082-5,Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830),Eliopoulos,2011,1
10.1093/clinids/10.4.860,Plasmid-Mediated  -Lactamase (TEM-7) Involved in Resistance to Ceftazidime and Aztreonam,Gutmann,2011,1
10.1128/aac.45.9.2598-2603.2001,"GES-2, a Class A β-Lactamase from
            <i>Pseudomonas aeruginosa</i>
            with Increased Hydrolysis of Imipenem",Poirel,2002,1
10.1128/aac.39.1.185,PCR mapping of integrons reveals several novel combinations of resistance genes,Lévesque,2012,1
10.1128/aac.24.3.343,Determination of ceftazidime in biological fluids by using high-pressure liquid chromatography,Myers,2012,1
10.1093/jac/35.2.333,The comparative inhibitory and bactericidal activities of meropenem and imipenem against <i>Acinetobacter</i> spp. and Enterobacteriaceae resistant to second generation cephalosporins,MacGowan,2007,1
10.1128/aac.35.6.1174,Imipenem- and meropenem-resistant mutants of Enterobacter cloacae and Proteus rettgeri lack porins,Raimondi,2012,1
10.1111/j.1574-6976.2011.00277.x,Analysis of antibiotic resistance regions in Gram-negative bacteria,Partridge,2011,2
10.1093/jac/dks012,Blood and CSF monitoring of cefepime-induced neurotoxicity: nine case reports,Durand-Maugard,2012,1
10.1128/aac.01595-08,High Cefepime Plasma Concentrations and Neurological Toxicity in Febrile Neutropenic Patients with Mild Impairment of Renal Function,Lamoth,2010,2
10.1128/aac.00329-06,"Randomized, Open-Label, Comparative Study of Piperacillin-Tazobactam Administered by Continuous Infusion versus Intermittent Infusion for Treatment of Hospitalized Patients with Complicated Intra-Abdominal Infection",Lau,2006,2
10.1128/aac.49.12.4920-4927.2005,"Optimization of Meropenem Minimum Concentration/MIC Ratio To Suppress In Vitro Resistance of
            <i>Pseudomonas aeruginosa</i>",Tam,2005,1
10.1086/424849,"Selection of a Moxifloxacin Dose That Suppresses Drug Resistance in<i>Mycobacterium tuberculosis,</i>by Use of an In Vitro Pharmacodynamic Infection Model and Mathematical Modeling",Gumbo,2004,1
10.1016/0034-5687(71)90028-4,Morphometric estimation of pulmonary diffusion capacity,Burri,2003,1
10.1136/adc.35.184.544,The Number of Alveoli in the Terminal Respiratory Unit of Man During Late Intrauterine Life and Childhood,Emery,2008,1
10.1128/aac.42.11.2966,Prospective Randomized Comparison of Imipenem-Cilastatin and Piperacillin-Tazobactam in Nosocomial Pneumonia or Peritonitis,Jaccard,2018,1
10.1007/bf01745248,Piperacillin/tazobactam in the treatment of polymicrobial infections,Gorbach,2005,1
10.1001/archsurg.1988.01400270056008,Prospective Study Comparing Imipenem-Cilastatin With Clindamycin and Gentamicin for the Treatment of Serious Surgical Infections,Hackford,2011,1
10.1128/aac.02374-13,Characterization of the Population Pharmacokinetics of Ampicillin in Neonates Using an Opportunistic Study Design,Tremoulet,2014,1
10.1038/jp.2009.192,Effect of ampicillin on the bleeding time of neonatal intensive care unit patients,Sheffield,2009,1
10.3109/14017438509102820,Effect of High-Dose Ampicillin and Cloxacillin on Bleeding Time and Bleeding in Open-Heart Surgery,Pillgram-Larsen,2007,1
10.1111/j.1600-0609.1983.tb01515.x,Effect of Prophylactic High-Dose Treatment with Ampicillin and Cloxacillin on Bleeding Time and Bleeding in Patients Undergoing Elective Vascular Surgery,Wisløff,2010,1
10.3181/00379727-142-36980,"Effects of Penicillin G on Platelet Aggregation, Release, and Adherence to Collagen",Cazenave,2013,1
10.1093/jhmas/jrq003,"Antibiotics and the Social History of the Controlled Clinical Trial, 1950-1970",Podolsky,2010,1
10.1007/s10096-019-03535-w,Target attainment of cefotaxime in critically ill children with meningococcal septic shock as a model for cefotaxime dosing in severe pediatric sepsis,Hartman,2019,1
10.1093/cid/cis857,Clinical Outcomes With Extended or Continuous Versus Short-term Intravenous Infusion of Carbapenems and Piperacillin/Tazobactam: A Systematic Review and Meta-analysis,Falagas,2012,1
10.1128/aac.49.5.1881-1889.2005,Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers,Krueger,2005,2
10.1007/bf02005446,"Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC",Hanberger,2005,1
10.1007/bf01644943,Bacterial kill rates of amoxycillin and ampicillin at exponentially diminishing concentrations simulating in vivo conditions,Bergan,2005,1
10.2165/00003495-197509020-00002,Amoxycillin,Brogden,2007,1
10.1016/j.ijantimicag.2010.06.008,Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept,Roberts,2010,2
10.1093/jac/dkp139,Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution,Roberts,2009,1
10.1177/0091270003257225,Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem,Kuti,2003,1
10.1592/phco.23.8.988.32878,Pharmacokinetics of Meropenem 0.5 and 2 g Every 8 Hours as a 3-Hour Infusion,Dandekar,2004,1
10.1097/00005373-198603000-00005,The Efficacy of Cefoxitin vs. Clindamycin/Gentamicin in Surgically Treated Stab Wounds of the Bowel,HESELTINE,2006,1
10.1186/1471-2334-5-1,Toxicity after prolonged (more than four weeks) administration of intravenous colistin,Falagas,2005,2
10.1345/aph.19370,Safety and Tolerability of Bolus Intravenous Colistin in Acute Respiratory Exacerbations in Adults with Cystic Fibrosis,Conway,2003,1
10.1159/000400132,Polymyxin Antibiotics,Bergan,2015,1
10.1186/cc13938,Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy,Ulldemolins,2014,2
10.1016/s0140-6736(00)02430-2,Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial,Ronco,2002,1
10.1681/asn.v81111,Predicting mortality in intensive care patients with acute renal failure treated with dialysis.,Douma,2021,1
10.1016/j.bcp.2005.10.038,The role of pharmacodynamic research in the assessment and development of new antibacterial drugs,Lister,2005,3
10.1093/jac/31.suppl_d.159,The post-antibiotic sub-MIC effect in vitro and in vivo,Cars,2012,1
10.1002/bjs.1800750822,Blood transfusion and infectious complications following colorectal cancer surgery,Tartter,2007,1
10.1093/clinids/3.6.1151,Cytomegalovirus Infections Following Renal Transplantation,Glenn,2011,1
10.1093/bioinformatics/btu031,InterProScan 5: genome-scale protein function classification,Jones,2014,1
10.1093/nar/gkr948,InterPro in 2011: new developments in the family and domain prediction database,Hunter,2011,1
10.1093/nar/gkq313,A new bioinformatics analysis tools framework at EMBL-EBI,Goujon,2010,1
10.1093/nar/gkp302,Web services at the European Bioinformatics Institute-2009,Mcwilliam,2009,1
10.1093/nar/28.1.235,The Protein Data Bank,Berman,2002,1
10.1074/jbc.m311373200,Structural Determinants of Substrate Binding to Bacillus cereus Metallo-β-lactamase,Rasia,2004,1
10.1016/s1074-5521(03)00070-x,Analysis of the Importance of the Metallo-β-Lactamase Active Site Loop in Substrate Binding and Catalysis,Moali,2003,1
10.1016/s1074-5521(98)90632-9,Antibiotic sensitization using biphenyl tetrazoles as potent inhibitors of Bacteroides fragilis metallo-β-lactamase,Toney,2004,1
10.1128/aac.41.2.223,Carbapenem-hydrolyzing beta-lactamases,Rasmussen,2018,1
10.1159/000007223,Susceptibility Surveillance among Gram-Negative Bacilli at a Cancer Center,Jacobson,2003,1
10.1056/nejm199305063281808,Management of Fever in Patients with Cancer and Treatment-Induced Neutropenia,Wood,2002,1
10.1038/bjc.1987.295,Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer,Bronchud,2011,1
10.1016/j.cmi.2018.11.020,Therapeutic drug monitoring of imipenem and the incidence of toxicity and failure in hospitalized patients: a retrospective cohort study,Bricheux,2018,2
10.1016/j.ijantimicag.2014.12.017,"Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study",Huttner,2015,1
10.1128/aac.40.1.105,Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin,Dreetz,2018,2
10.1016/j.ijantimicag.2014.01.027,Prolonged infusion versus intermittent boluses of β-lactam antibiotics for treatment of acute infections: a meta-analysis,Teo,2014,1
10.1128/aac.35.9.1834,Pharmacodynamic effects of subinhibitory concentrations of beta-lactam antibiotics in vitro,Odenholt-Tornqvist,2012,1
10.1128/aac.35.7.1413,Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model,Fantin,2012,1
10.1001/jama.299.17.2048,Corticosteroids and Mortality in Children With Bacterial Meningitis,Mongelluzzo,2008,1
10.1016/j.ijantimicag.2016.07.015,In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model,Soon,2016,1
10.1128/aac.02635-15,Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam–β-Lactamase Inhibitor Combinations,Soon,2016,1
10.1128/aac.02310-13,Relationship between Ceftolozane-Tazobactam Exposure and Selection for Pseudomonas aeruginosa Resistance in a Hollow-Fiber Infection Model,VanScoy,2014,1
10.1128/aac.01753-09,"Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions",Ge,2010,2
10.1086/646178,Pharmacodynamic Properties of Antibiotics: Application to Drug Monitoring and Dosage Regimen Design,Ebert,2009,1
10.1097/00000441-197709000-00010,A comparative trial of sisomicin therapy by intermittent versus continuous infusion,FELD,2006,1
10.1016/0920-1211(93)90070-n,Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin,Taylor,2003,1
10.1016/0091-3057(77)90036-3,A new device for the rapid measurement of impaired motor function in mice,Coughenour,2002,1
10.1111/j.1600-0773.1973.tb01525.x,The Rotacone: A New Apparatus for Measuring Motor Coordination in Mice,Christensen,2010,1
10.1007/bf00401346,Drug effects on motor coordination,Watzman,2004,1
10.1002/jps.2600500318,Evaluation of Certain Psychopharmacological Compounds,Furgiuele,2006,1
10.1176/ajp.115.4.360,NOTE ON METHOXYDONE (AHR-233),DENBER,2014,3
10.1038/sj.bjp.0703927,"Pharmacokinetics of pefloxacin and its interaction with cyclosporin A, a P-glycoprotein modulator, in rat blood, brain and bile, using simultaneous microdialysis",Tsai,2005,1
10.1128/aac.25.4.463,"Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans",Montay,2012,1
10.1128/aac.40.5.1139,Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation,Amaker,2018,1
10.1007/s00134-013-3187-2,Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial,De Waele,2013,4
10.1128/aac.43.10.2559,Low Plasma Cefepime Levels in Critically Ill Septic Patients: Pharmacokinetic Modeling Indicates Improved Troughs with Revised Dosing,Lipman,2018,1
10.1128/aac.40.3.691,Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections,Benko,2018,1
10.1086/374337,Treatment of Multidrug‐Resistant<i>Acinetobacter baumannii</i>Ventilator‐Associated Pneumonia (VAP) with Intravenous Colistin: A Comparison with Imipenem‐Susceptible VAP,Garnacho‐Montero,2003,1
10.1128/aac.46.6.1946-1952.2002,"Efficacy of Colistin versus β-Lactams, Aminoglycosides, and Rifampin as Monotherapy in a Mouse Model of Pneumonia Caused by Multiresistant
            <i>Acinetobacter baumannii</i>",Montero,2002,1
10.1099/00222615-46-9-721,"Clinical importance and antibiotic resistance of Acinetobacter spp.: Proceedings of a symposium held on 4-5 November 1996 at Eilat, Israel",TOWNER,2009,1
10.1089/sur.2018.141,Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients,Stein,2018,1
10.1093/jac/43.2.309,Continuous infusion ceftazidime in intensive care: a randomized controlled trial,Lipman,2002,2
10.1094/mpmi-6-553,Nucleotide Sequence and Properties of the<i>hrm</i>A Locus Associated with the<i>Pseudomonas syringae</i>pv.<i>syringae</i>61<i>hrp G</i>ene Cluster,Heu,2011,1
10.1021/ci980185h,Comparing 3D Pharmacophore Triplets and 2D Fingerprints for Selecting Diverse Compound Subsets,Matter,2002,1
10.1021/ci00017a025,Flexible 3D searching: The directed tweak technique,Hurst,2005,1
10.2106/00004623-197961070-00003,Clinical study of total ankle replacement with gait analysis. A preliminary report.,Demottaz,2016,1
10.1046/j.1365-2958.2003.03673.x,"Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa",McPhee,2003,1
10.1016/s0092-8674(00)00092-1,A Signal Transduction System that Responds to Extracellular Iron,Wösten,2004,1
10.1093/emboj/19.8.1861,A small protein that mediates the activation of a two-component system by another two-component system,Kox,2002,1
10.1002/(sici)1521-3773(19990301)38:5<643::aid-anie643>3.0.co;2-g,Statistical Investigation into the Structural Complementarity of Natural Products and Synthetic Compounds,Henkel,2002,1
10.1093/jac/dkaa468,Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study,Wu,2020,2
10.1126/science.107.2767.44,"A Paradoxical Zone Phenomenon in the Bactericidal Action of Penicillin
            <i>in Vitro</i>",Eagle,2006,1
10.2165/11539220-000000000-00000,The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients,Ulldemolins,2010,1
10.2165/00003088-197803020-00004,Diseases and Drug Protein Binding,Tillement,2007,1
10.1093/jac/dku322,Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia,Barber,2014,1
10.1093/cid/cir340,Use of Antistaphylococcal  -Lactams to Increase Daptomycin Activity in Eradicating Persistent Bacteremia Due to Methicillin-Resistant Staphylococcus aureus: Role of Enhanced Daptomycin Binding,Dhand,2011,1
10.1097/pcc.0000000000000847,Epidemiology of Sepsis in Children Admitted to PICUs in South America*,de Souza,2016,1
10.1128/jb.59.5.625-643.1950,"THE EFFECTIVE CONCENTRATIONS OF PENICILLIN IN VITRO AND IN VIVO FOR STREPTOCOCCI, PNEUMOCOCCI, AND TREPONEMA PALLIDUM",Eagle,2020,1
10.1016/j.jcma.2011.01.017,Cefepime-related encephalopathy in peritoneal dialysis patients,Lin,2011,1
10.1016/j.jpba.2017.05.037,"Therapeutic drug monitoring of beta-lactam antibiotics – Influence of sample stability on the analysis of piperacillin, meropenem, ceftazidime and flucloxacillin by HPLC-UV",Pinder,2017,1
10.1128/aac.00521-12,Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial Infections,Felton,2012,1
10.1016/j.ijantimicag.2009.10.008,First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis,Roberts,2009,2
10.1097/qco.0000000000000494,How to optimize antibiotic pharmacokinetic/pharmacodynamics for Gram-negative infections in critically ill patients,Heffernan,2018,1
10.1128/aac.39.3.650,"Experience with a once-daily aminoglycoside program administered to 2,184 adult patients",Nicolau,2012,1
10.1002/phar.1567,"Pharmacokinetics of Continuous-Infusion Meropenem for the Treatment of <i>Serratia marcescens</i>
 Ventriculitis in a Pediatric Patient",Cies,2015,1
10.1093/jac/45.3.329,High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures,Pea,2002,1
10.1093/jac/dku567,Colistin and doripenem combinations against <i>Pseudomonas aeruginosa</i>: profiling the time course of synergistic killing and prevention of resistance,Ly,2015,3
10.1016/j.jcf.2008.02.003,Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients,Johansen,2008,1
10.1002/(sici)1099-0496(199705)23:5<330::aid-ppul4>3.0.co;2-o,Antibiotic treatment of initial colonization withPseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis,Frederiksen,2002,1
10.1016/0140-6736(93)92422-p,Pathogenesis of cystic fibrosis,Koch,2003,1
10.1126/science.2772657,Identification of the Cystic Fibrosis Gene: Chromosome Walking and Jumping,Rommens,2006,1
10.1038/330752a0,Phosphorylation fails to activate chloride channels from cystic fibrosis airway cells,Schoumacher,2003,1
10.1097/qco.0b013e328332e672,Colistin in the 21st century,Nation,2009,1
10.1179/146532809x440761,Successful treatment of multidrug-resistant<i>Acinetobacter baumanii</i>ventriculitis with intravenous and intraventricular colistin,Dalgic,2009,1
10.1097/00006454-200003000-00029,NOSOCOMIAL ACINETOBACTER MENINGITIS,Kralinsky,2003,1
10.1007/bf01962597,EndemicAcinetobacter anitratus in a surgical intensive care unit: Mechanical ventilators as reservoir,Vandenbroucke-Grauls,2005,1
10.7326/0003-4819-77-5-701,Nosocomial Respiratory Infections with Gram-Negative Bacilli,JOHANSON,2013,1
10.1007/bf02390681,Origin and impact of plasmid-mediated extended-spectrum beta-lactamases,Philippon,2006,1
10.1128/aac.34.9.1725,Nucleotide sequence and phylogeny of SHV-2 beta-lactamase,Huletsky,2012,1
10.1592/phco.24.1.8.34804,"Pharmacodynamics of Meropenem and Imipenem Against Enterobacteriaceae,<i>Acinetobacter baumannii</i>, and<i>Pseudomonas aeruginosa</i>",Kuti,2004,1
10.1093/jac/47.3.247,"Of Pseudomonas, porins, pumps and carbapenems",Livermore,2002,1
10.1128/aac.00833-10,"<i>In Vitro</i>
            Spectrum of Activity of Finafloxacin, a Novel, pH-Activated Fluoroquinolone, under Standard and Acidic Conditions",Stubbings,2011,1
10.1093/jac/dkq375,Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance,Emrich,2010,1
10.1093/jac/44.3.343,"The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model",Aeschlimann,2002,1
10.1128/aac.43.2.335,"Effects of NorA Inhibitors on In Vitro Antibacterial Activities and Postantibiotic Effects of Levofloxacin, Ciprofloxacin, and Norfloxacin in Genetically Related Strains of
            <i>Staphylococcus aureus</i>",Aeschlimann,2018,1
10.1128/aac.35.12.2562,Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus,Nakanishi,2012,1
10.1186/1471-2334-6-55,Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases,Zuluaga,2006,2
10.1128/aac.33.6.980,Influence of etoposide and cyclophosphamide on the efficacy of cloxacillin and erythromycin in an experimental staphylococcal infection,Calame,2012,1
10.1021/jm900999h,Structure−Activity Relationships of Polymyxin Antibiotics,Velkov,2009,1
10.7164/antibiotics.44.517,The outer membrane permeability-increasing action of deacylpolymyxins.,VILJANEN,2012,1
10.1542/peds.2006-2353,Patient and Hospital Correlates of Clinical Outcomes and Resource Utilization in Severe Pediatric Sepsis,Odetola,2007,1
10.1177/0272989x9601600405,Predicting In-hospital Mortality for Stroke Patients,Iezzoni,2007,1
10.1097/00001888-199005000-00012,The problem of late hospitalization,Gonnella,2006,1
10.1016/s0149-2918(04)80001-8,Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem,Mattoes,2004,1
10.1093/cid/cis856,"Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Double-Blind, Randomized Controlled Trial",Dulhunty,2012,1
10.1016/j.jchromb.2010.05.027,Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection,McWhinney,2010,1
10.1097/00006454-199603000-00015,Pharmacokinetics and pharmacodynamics of antibiotics in otitis media,CRAIG,2003,1
10.1128/aac.36.4.856,"Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin",Spangler,2012,1
10.1128/aac.00334-06,The Relationship between Quinolone Exposures and Resistance Amplification Is Characterized by an Inverted U: a New Paradigm for Optimizing Pharmacodynamics To Counterselect Resistance,Tam,2006,1
10.1086/430611,Bacterial‐Population Responses to Drug‐Selective Pressure: Examination of Garenoxacin's Effect on<i>Pseudomonas aeruginosa</i>,Tam,2005,1
10.1002/jcph.705,Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates,Wilbaux,2016,2
10.1007/s40262-013-0036-y,Population Pharmacokinetics of Tobramycin in Patients With and Without Cystic Fibrosis,Hennig,2013,2
10.1097/00007691-199906000-00004,Population Pharmacokinetics of Aminoglycoside Antibiotics in Patients With Cystic Fibrosis,Campbell,2003,1
10.1097/00007691-199404000-00003,Suggestions for the Optimization of the Initial Tobramycin Dose in Adolescent and Adult Patients with Cystic Fibrosis,Touw,2006,1
10.1002/jps.2600621042,"Rapid, Simultaneous GLC Determination of Phenobarbital, Primidone, and Diphenylhydantoin",Perchalski,2006,1
10.1016/0009-8981(70)90048-3,"Quantitative estimation of diphenylhydantoin, primidone and phenobarbital in plasma by gas-liquid chromatography",Kupferberg,2003,1
10.1021/ac60280a016,Gas-chromatographic method for determination of diphenylhydantoin blood level,Sabih,2005,1
10.1016/s0731-7085(01)00706-3,HPLC separation of antibiotics present in formulated and unformulated samples,Joshi,2002,1
10.1016/s0731-7085(99)00218-6,Validation of a reversed-phase LC method for quantitative analysis of intravenous admixtures of ciprofloxacin and metronidazole,Vega,2002,1
10.1128/aac.02089-15,Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children,Nichols,2015,2
10.1177/0897190011406984,Development and Implementation of a Piperacillin-Tazobactam Extended Infusion Guideline,Heinrich,2011,1
10.1016/j.diagmicrobio.2009.03.002,Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections,Patel,2009,1
10.1128/aac.01318-06,"Population Pharmacokinetics and Pharmacodynamics of Continuous versus Short-Term Infusion of Imipenem-Cilastatin in Critically Ill Patients in a Randomized, Controlled Trial",Sakka,2007,1
10.1128/aac.49.1.461-463.2005,Pharmacodynamic Evaluation of Extending the Administration Time of Meropenem using a Monte Carlo Simulation,Lomaestro,2004,1
10.1093/clinids/6.supplement_4.s870,Failure of a Once-Daily Regimen of Cefonicid for Treatment of Endocarditis Due to Staphylococcus aureus,Chambers,2011,1
10.1186/cc3995,,Falagas,2006,1
10.1093/clinids/24.supplement_1.s139,Control of Nosocomial Antimicrobial-Resistant Bacteria: A Strategic Priority for Hospitals Worldwide,Goldmann,2011,1
10.1007/s15010-002-1083-8,Nosocomial Pneumonia: A Cost-of-Illness Analysis,Dietrich,2003,1
10.1001/archinte.160.7.1017,Handwashing Compliance by Health Care Workers,Bischoff,2003,1
10.7326/0003-4819-57-2-214,The Treatment of Gram-negative Bacillary Infections with Colistin,FEKETY,2013,1
10.1208/s12248-011-9258-9,Performance and Robustness of the Monte Carlo Importance Sampling Algorithm Using Parallelized S-ADAPT for Basic and Complex Mechanistic Models,Bulitta,2011,1
10.1023/a:1020707208521,,Krzyzanski,2003,1
10.1016/0022-2836(86)90385-2,Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes,Studier,2004,1
10.1016/0092-8674(83)90287-8,Termination of transcription in E. coli,Michael Holmes,2004,1
10.1086/431672,Tigecycline: A New Glycylcycline for Treatment of Serious Infections,Noskin,2005,1
10.1128/aac.47.6.1867-1874.2003,"Antimicrobial Resistance in Respiratory Tract
            <i>Streptococcus pneumoniae</i>
            Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002",Zhanel,2003,1
10.1128/aac.43.10.2504,"Prevalence of Antimicrobial Resistance in Respiratory Tract Isolates of
            <i>Streptococcus pneumoniae</i>
            : Results of a Canadian National Surveillance Study",Zhanel,2018,1
10.1128/aac.34.3.467,Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae,Mazzulli,2012,1
10.1097/01.ccm.0000275389.31974.22,"Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy*",Garnacho-Montero,2007,1
10.1378/chest.108.6.1655,The Effect of Late-Onset Ventilator-Associated Pneumonia in Determining Patient Mortality,Kollef,2008,1
10.1001/archinte.1988.00380050165024,Nosocomial Infection and Fatality in Medical and Surgical Intensive Care Unit Patients,Craven,2011,1
10.1111/j.1469-0691.2010.03130.x,Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients,Zamorano,2010,1
10.1128/aac.49.6.2510-2511.2005,In Vitro Activity of Doripenem (S-4661) against Multidrug-Resistant Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis,Chen,2005,1
10.1093/jac/dkh369,Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections,Sobieszczyk,2004,2
10.1111/j.1600-0447.1977.tb06678.x,"A repeated dose comparison of three benzodiazepine derivatives (nitrazepam, flurazepam and flunitrazepam) on subjective appraisals of sleep and measures of psychomotor performance the morning following night-time medication",Hindmarch,2007,1
10.1192/bjp.124.5.482,Effects of Hypnotics on Anxious Patients,Malpas,2008,1
10.1136/bmj.1.5850.417-b,Effects of tranquillizers and hypnotics on driving.,Legg,2009,1
10.1128/jcm.02483-16,Same-Day Diagnostic and Surveillance Data for Tuberculosis via Whole-Genome Sequencing of Direct Respiratory Samples,Votintseva,2017,1
10.1016/s1473-3099(15)00062-6,Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study,Walker,2015,1
10.1038/ng.2878,Evolution and transmission of drug-resistant tuberculosis in a Russian population,Casali,2014,1
10.1126/science.272.5268.1641,"Compensatory
            <b>
              <i>ahp</i>
            </b>
            C Gene Expression in Isoniazid-Resistant
            <b>
              <i>Mycobacterium tuberculosis</i>
            </b>",Sherman,2006,1
10.1073/pnas.92.14.6630,Identification of a gene involved in the biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis.,Yuan,2006,1
10.1099/00221287-137-12-2681,An IS1-like element is responsible for high-level synthesis of extended-spectrum  -lactamase TEM-6 in Enterobacteriaceae,Goussard,2009,1
10.1007/978-3-642-85921-2_16,Pharmacokinetic Studies on Carbamazepine in Volunteers and in Epileptic Patients,Morselli,2012,1
10.1093/jac/19.6.823,Bilirubin displacement by ceftriaxone in neonates: evaluation by determination of ‘free’ bilirubin and erythrocyte-bound bilirubin,Gulian,2007,1
10.1016/j.jcf.2006.12.007,Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis,Touw,2007,1
10.1128/aac.27.4.520,"Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans",Contrepois,2012,1
10.1093/jac/dkx209,Too much of a good thing: a retrospective study of β-lactam concentration–toxicity relationships,Imani,2017,2
10.1592/phco.23.3.369.32100,Retrospective Review of Neurotoxicity Induced by Cefepime and Ceftazidime,Chow,2004,1
10.1136/jnnp.55.4.333,Ceftazidime encephalopathy: absence status and toxic hallucinations.,Jackson,2008,1
10.1002/ana.410270508,Peduncular hallucinosis associated with isolated infarction of the substantia nigra pars reticulata,McKee,2005,1
10.1002/cne.901840104,An autoradiographic examination of corticocortical and subcortical projections of the mediodorsal-projection (prefrontal) cortex in the rat,Beckstead,2005,1
10.1016/0006-8993(68)90052-8,Evaluation of a radioautographic neuroanatomical tracing method,Lasek,2003,1
10.3109/10520293509116018,Chlorate-Osmic-Formalin Method for Staining Degenerating Myelin,Swank,2007,1
10.1128/aac.01045-16,A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants,Leroux,2016,3
10.1016/s0378-3782(12)70019-1,Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units,Hornik,2012,1
10.1542/peds.110.6.1037,Annual Summary of Vital Statistics—2001,MacDorman,2004,1
10.1093/aje/154.4.307,Trends in Preterm Birth and Neonatal Mortality among Blacks and Whites in the United States from 1989 to 1997,Demissie,2002,1
10.1038/jp.2010.191,"Why do families of sick newborns accept hospital care? a community-based cohort study in Karachi, Pakistan",Owais,2011,1
10.2307/2137032,"Help-Seeking Behavior, Use, and Satisfaction Among Frequent Primary Care Users in Santiago de Chile",Scarpaci,2006,1
10.1007/bf02723654,Clinico-bacteriological study of neonatal septicemia in Hubli,Tallur,2007,1
10.1007/bf02749536,Changing bacteriological patterns in neonatal septicaemia,Monga,2008,1
10.1016/s0140-6736(65)92955-7,NEONATAL INFECTIONS WITH PSEUDOMONAS AERUGINOSA ASSOCIATED WITH CONTAMINATED RESUSCITATION EQUIPMENT,Bassett,2003,1
10.1016/s0022-3476(52)80102-7,Pseudomonas infections in infants and children,Geppert,2006,1
10.1016/j.ijantimicag.2007.05.014,Optimising piperacillin/tazobactam dosing in paediatrics,Tornøe,2007,1
10.1128/cmr.00058-07,"<i>Acinetobacter baumannii</i>
            : Emergence of a Successful Pathogen",Peleg,2008,1
10.1016/j.jcf.2005.05.018,Eradication of early Pseudomonas aeruginosa infection,Høiby,2005,1
10.1128/aac.02243-16,Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?,Marshall,2017,3
10.1128/aac.01585-15,Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam,Pagès,2015,2
10.1128/aac.05305-11,The Class A β-Lactamase FTU-1 Is Native to Francisella tularensis,Antunes,2011,1
10.1023/a:1007537405242,,Guryčová,2002,1
10.1093/clinids/24.5.786,A Meta-Analysis of Extended-Interval Dosing Versus Multiple Daily Dosing of Aminoglycosides,Bailey,2011,1
10.1093/jac/dkh299,Antibiotic usage in intensive care units: a pharmaco-epidemiological multicentre study,Malacarne,2004,1
10.1016/s0378-4347(00)85120-8,"Determination of ampicillin, amoxicillin, cephalexin, and cepharadine in plasma by high-performance liquid chromatography using fluorometric detection",Miyazaki,2002,1
10.1016/0009-8981(77)90243-1,"A simple, rapid fluorimetric assay of amoxycillin in plasma",Barbhaiya,2003,1
10.1248/cpb.22.1910,Fluorometric determination of ampicillin.,MIYAZAKI,2011,1
10.1016/s1473-3099(19)30403-7,"Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial",Kollef,2019,1
10.1111/resp.13115,The respiratory threat posed by multidrug resistant Gram-negative bacteria,Rodrigo-Troyano,2017,1
10.1186/1471-2466-14-103,Pseudomonas aeruginosaisolates in severe chronic obstructive pulmonary disease: characterization and risk factors,Gallego,2014,1
10.1183/09031936.00003309,Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study,Garcia-Vidal,2009,1
10.1128/aac.33.9.1617,"Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3, and genospecies 6)",Traub,2012,1
10.1007/s00228-007-0307-3,Therapeutic amoxicillin levels achieved with oral administration in term neonates,Gras-Le Guen,2007,1
10.1542/peds.2005-2824,Factors Influencing the Composition of the Intestinal Microbiota in Early Infancy,Penders,2006,1
10.1016/s0924-8579(01)00329-6,Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia,Nicolau,2002,1
10.1097/00003246-199905000-00020,Nosocomial infections in medical intensive care units in the United States,Richards,2003,1
10.1016/s0196-6553(96)90036-x,Severity of illness scoring systems to adjust nosocomial infection rates: A review and commentary,Keita-Perse,2004,1
10.1097/00003246-199102000-00008,Use of the Pediatric Risk of Mortality score to predict nosocomial infection in a pediatric intensive care unit,POLLOCK,2006,1
10.1128/aac.1.4.283,Novel Method for Detection of β-Lactamases by Using a Chromogenic Cephalosporin Substrate,O'Callaghan,2012,1
10.1016/j.ijantimicag.2018.11.017,Population pharmacokinetics and dosing optimization of latamoxef in neonates and young infants,Qi,2018,1
10.1159/000346629,Impact of Severe Sepsis on Serum and Urinary Biomarkers of Acute Kidney Injury in Critically Ill Children: An Observational Study,Di Nardo,2013,1
10.1186/cc12705,Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?,Carlier,2013,1
10.1213/ane.0b013e3181f7107d,Augmented Creatinine Clearance in Traumatic Brain Injury,Udy,2010,1
10.1056/nejm197810262991703,Increased Glomerular Filtration Rate in Patients with Major Burns and Its Effect on the Pharmacokinetics of Tobramycin,Loirat,2010,1
10.1016/0009-8981(65)90028-8,Analyse automatique de la créatinine dans le sérum et dans l'urine valeurs “normales” chez l'homme de la créatininémie et de la clearance,Zender,2003,1
10.1016/0006-3002(52)90011-5,Creatinine estimation in blood serum a new method,Koštíř,2003,1
10.1016/s0021-9258(18)87378-1,A SYSTEM OF BLOOD ANALYSIS,Folin,2021,1
10.1037/h0023358,Developmental study of color-word interference.,Schiller,2006,1
10.1007/s40262-017-0602-9,Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children,Béranger,2017,1
10.1055/s-0034-1398490,Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development,Abdul-Aziz,2015,1
10.1212/wnl.39.10.1294,Valproate prevents the recurrence of absence status,Berkovic,2012,1
10.1016/j.ijid.2003.09.003,Cefepime-induced encephalopathy,Dakdouki,2003,1
10.1001/archinte.1994.00420050158014,Ceftazidime-Related Nonconvulsive Status Epilepticus,Klion,2011,1
10.5694/j.1326-5377.1977.tb113913.x,EVALUATION OF NEPHROTOXIC AND OTOTOXIC EFFECTS OF TOBRAMYCIN IN WORLDWIDE STUDY,Bendush,2019,1
10.1288/00005537-196702000-00002,POSSIBLE EFFECTS OF VARIOUS OTOTOXIC DRUGS UPON THE ATP-HYDROLYZING SYSTEM IN THE STRIA VASCULARIS AND SPIRAL LIGAMENT OF THE GUINEA PIG,Linuma,2006,1
10.1592/phco.23.15.1545.31969,Comparative Pharmacokinetic Analysis by Standard Two-Stage Method versus Nonparametric Population Modeling,Tam,2004,1
10.1016/s0002-9343(84)80074-1,Role for Dual Individualization with Cefmenoxime,Schentag,2014,1
10.1093/jac/14.1.81,Cefmenoxime in the treatment of nosocomial pneumonias in critical care patients,Reitberg,2007,1
10.1164/ajrccm.156.4.9701046,Scheduled Change of Antibiotic Classes,KOLLEF,2013,1
10.1378/chest.102.5_supplement_1.553s,Patient Selection for Clinical Investigation of Ventilator-Associated Pneumonia,Pingleton,2008,1
10.1378/chest.91.2.233,Use of the Protected Specimen Brush in Patients with Endotracheal or Tracheostomy Tubes,Baughman,2007,1
10.1146/annurev.me.27.020176.002015,The Adult Respiratory Distress Syndrome,Hopewell,2003,1
10.2217/fmb.13.39,Pharmacology of polymyxins: new insights into an ‘old’ class of antibiotics,Velkov,2013,1
10.1007/s00228-003-0608-0,Paracetamol and metabolite pharmacokinetics in infants,van der Marel,2003,1
10.2165/00003088-200847040-00002,Facilitation of Drug Evaluation in Children by Population Methods and Modelling†,Tod,2009,1
10.1002/(sici)1097-0258(19981030)17:20<2313::aid-sim935>3.0.co;2-v,A Markov mixed effect regression model for drug compliance,Girard,2002,1
10.1208/aapsj0901007,A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples,Bauer,2007,1
10.1007/s10928-005-0062-y,Non-Linear Mixed Effects Modeling – From Methodology and Software Development to Driving Implementation in Drug Development Science,Pillai,2005,1
10.1128/aac.41.11.2433,"Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy",Vanhove,2018,1
10.1016/j.mib.2006.08.009,Combinatorial genetic evolution of multiresistance,Walsh,2006,1
10.1164/rccm.201601-0024oc,Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials,Roberts,2016,1
10.1128/aac.00294-06,Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections,Li,2007,1
10.1097/pcc.0b013e31823c980f,Epidemiology of sepsis in pediatric intensive care units,Jaramillo-Bustamante,2012,1
10.1097/01.pcc.0000059421.13161.88,Multiple organ dysfunction syndrome in children*,Tantale??n,2003,1
10.1097/00003246-199606000-00031,Sepsis/septic shock,Hinshaw,2003,1
10.1152/jappl.1991.71.1.307,Role of neutrophils in endotoxin-mediated microvascular injury in hamsters,Matsuda,2017,1
10.1086/432803,Overview of Nosocomial Infections Caused by Gram-Negative Bacilli,Weinstein,2005,1
10.3201/eid1101.040001,Multidrug-Resistant<i>Acinetobacter baumannii</i>,Abbo,2012,1
10.1086/320183,"Emerging Importance of Multidrug‐Resistant<i>Acinetobacter</i>Species and<i>Stenotrophomonas maltophilia</i>as Pathogens in Seriously Ill Patients: Geographic Patterns, Epidemiological Features, and Trends in the SENTRY Antimicrobial Surveillance Program (1997–1999)",Gales,2002,1
10.1099/00207713-43-3-606,"Stenotrophomonas, a New Bacterial Genus for Xanthomonas maltophilia (Hugh 1980) Swings et al. 1983",Palleroni,2009,1
10.1186/cc2358,,Markou,2003,1
10.1016/j.patbio.2008.07.028,Pseudomonas aeruginosa et bêta-lactamines à l’heure de l’Europe,Cavallo,2008,1
10.1093/jac/dkm536,Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic–pharmacodynamic models with Monte Carlo simulation,Frei,2008,1
10.1086/510590,Piperacillin-Tazobactam for Pseudomonas aeruginosa Infection: Clinical Implications of an Extended-Infusion Dosing Strategy,Lodise,2007,1
10.1097/00003246-198510000-00009,APACHE II,KNAUS,2006,1
10.4103/ijmm.ijmm_17_278,Optimisation of Antimicrobial Dosing Based on Pharmacokinetic and Pharmacodynamic Principles,Ru Hoo,2018,2
10.1016/s0891-5520(03)00057-6,Pharmacodynamics and dosing of aminoglycosides,Turnidge,2005,1
10.1128/aac.21.5.721,Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients,Schentag,2012,1
10.1097/ftd.0b013e3181a8cc0a,In Vivo Glucuronidation Activity of Drugs in Neonates: Extensive Interindividual Variability Despite Their Young Age,Allegaert,2009,1
10.1213/00000539-199805000-00008,Clearance of Morphine in Postoperative Infants During Intravenous Infusion,Lynn,2011,1
10.1097/00000542-198702000-00005,Morphine Pharmacokinetics in Early Infancy,Lynn,2006,1
10.1097/00003246-199310000-00016,Predictability of creatinine clearance estimates in critically ill patients,ROBERT,2006,1
10.1007/bf01647733,Development of the faecal anaerobic microflora after Caesarean section and treatment with antibiotics in newborn infants,Bennel,2005,1
10.1099/00222615-15-2-189,The Microbial Ecology of the Large Bowel of Breastfed and Formula-fed Infants During the First Year of Life,Stark,2009,1
10.1371/journal.ppat.1007297,Pathogen-based precision medicine for drug-resistant tuberculosis,Gröschel,2018,2
10.1038/s41467-017-00721-2,A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide,Yadon,2017,1
10.1128/jcm.42.10.4498-4502.2004,"Detection of Mutations Associated with Isoniazid and Rifampin Resistance in
            <i>Mycobacterium tuberculosis</i>
            Isolates from Samara Region, Russian Federation",Nikolayevsky,2004,1
10.1128/jcm.40.2.712-714.2002,"Evaluation of a Rapid PCR-Based Epidemiological Typing Method for Routine Studies of
            <i>Mycobacterium tuberculosis</i>",Yates,2002,1
10.1128/jcm.36.11.3385-3388.1998,Evaluation of Strategies for Molecular Fingerprinting for Use in the Routine Work of a Mycobacterium Reference Unit,Wilson,2019,1
10.1128/jcm.34.7.1686-1690.1996,Heminested inverse PCR for IS6110 fingerprinting of Mycobacterium tuberculosis strains,Patel,2020,1
10.1016/s0002-9343(89)80611-4,Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients,Hilf,2004,1
10.1093/clinids/5.supplement_5.s837,Nosocomial Infections Due to Pseudomonas aeruginosa: Review of Recent Trends,Cross,2011,1
10.1086/381972,Clinical Relevance of Bacteriostatic versus Bactericidal Mechanisms of Action in the Treatment of Gram‐Positive Bacterial Infections,Pankey,2004,1
10.1016/0002-9343(76)90758-0,Clindamycin therapy of staphylococcus aureus endocarditis,Watanakunakorn,2004,1
10.1093/infdis/131.4.367,Antimicrobial Therapy of Experimental Endocarditis Caused by Staphylococcus aureus,Sande,2011,1
10.1006/jmbi.2000.4315,Predicting transmembrane protein topology with a hidden markov model: application to complete genomes11Edited by F. Cohen,Krogh,2002,1
10.1016/0022-2836(92)90934-c,Membrane protein structure prediction,von Heijne,2005,1
10.1002/j.1460-2075.1986.tb04699.x,Both hydrophobic domains of M13 procoat are required to initiate membrane insertion.,Kuhn,2018,1
10.1016/s0732-8893(00)00185-1,The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae,Ambrose,2002,1
10.1001/jama.279.2.125,Pharmacodynamics of Levofloxacin,Preston,2003,2
10.1016/j.ijid.2017.07.007,Rapid identification of a Mycobacterium tuberculosis full genetic drug resistance profile through whole genome sequencing directly from sputum,Nimmo,2017,1
10.1128/jcm.00486-15,Rapid Whole-Genome Sequencing of Mycobacterium tuberculosis Isolates Directly from Clinical Samples,Brown,2015,1
10.1183/09031936.00157212,"Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF",Weyer,2012,1
10.1016/s0022-3476(96)70336-0,Efficacy of gabapentin therapy in children with refractory partial seizures,Khurana,2005,1
10.1128/aac.01198-10,"Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-Producing
            <i>Klebsiella pneumoniae</i>",Endimiani,2010,1
10.1128/aac.01821-09,"<i>In Vitro</i>
            Activity of Penem-1 in Combination with β-Lactams against
            <i>bla</i>
            <sub>KPC</sub>
            -Possessing
            <i>Klebsiella pneumoniae</i>
            Isolates",Endimiani,2010,1
10.1128/aac.46.1.69-74.2002,"Pharmacodynamics of Gatifloxacin against
            <i>Streptococcus pneumoniae</i>
            in an In Vitro Pharmacokinetic Model: Impact of Area under the Curve/MIC Ratios on Eradication",Lister,2002,1
10.1172/jci108775,Corticosteroid Effect on Granulopoiesis in Mice after Cyclophosphamide,Joyce,2008,1
10.1139/m84-136,Chemical alterations in cell envelopes of <i>Pseudomonas aeruginosa</i> upon exposure to polymyxin: a possible mechanism to explain adaptive resistance to polymyxin,Gilleland Jr.,2010,1
10.1345/aph.1e271,Pharmacokinetics and Pharmacodynamics of Meropenem in Febrile Neutropenic Patients with Bacteremia,Ariano,2004,1
10.1016/s0149-2918(01)80103-x,Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients,Smith,2002,1
10.1007/s002800050397,A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941,Jodrell,2002,1
10.1093/jac/23.6.861,"Comparative pharmacokinetic study between lenampicillin, bacampicillin and amoxycillin",Sum,2007,1
10.1016/j.jinf.2012.01.015,Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy,Kubin,2012,1
10.1016/j.ijantimicag.2009.06.028,Clinical characteristics and risk factors of colistin-induced nephrotoxicity,Kim,2009,1
10.7326/0003-4819-73-3-491,Recovery from Colistimethate Nephrotoxicity,RANDALL,2013,1
10.1093/infdis/129.2.124,"Antibiotic Synergy in Experimental Infection with Pseudomonas. II. The Effect of Carbenicillin, Cephalothin, or Cephanone Combined with Tobramycin or Gentamicin",Andriole,2011,1
10.1128/aac.37.1.128,Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter,Neyfakh,2012,1
10.1016/j.coph.2017.10.014,Ensuring quality pharmacokinetic analyses in antimicrobial drug development programs,Lakota,2017,2
10.2165/00003088-199120040-00001,Noncompartmental Versus Compartmental Modelling in Clinical Pharmacokinetics,Gillespie,2007,1
10.1128/jcm.18.3.521-525.1983,Rapid detection of bacterial growth in blood cultures by bioluminescent assay of bacterial ATP,Molin,2020,1
10.1016/j.diagmicrobio.2012.11.024,Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011),Jones,2013,1
10.1128/aac.00286-06,In Vitro Activities of Dalbavancin and 12 Other Agents against 329 Aerobic and Anaerobic Gram-Positive Isolates Recovered from Diabetic Foot Infections,Goldstein,2006,1
10.1128/aac.47.6.1968-1971.2003,In Vitro Activities of Dalbavancin and Nine Comparator Agents against Anaerobic Gram-Positive Species and Corynebacteria,Goldstein,2003,1
10.1001/jama.287.3.321,Short-term Quality-of-Life Outcomes Following Laparoscopic-Assisted Colectomy vs Open Colectomy for Colon Cancer&lt;SUBTITLE&gt;A Randomized Trial&lt;/SUBTITLE&gt;,Weeks,2003,1
10.1186/s13054-015-0891-z,Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study,Shekar,2015,1
10.1007/s00134-007-0606-2,Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment,Mehta,2007,1
10.1093/nar/gki442,InterProScan: protein domains identifier,Quevillon,2005,1
10.1097/ccm.0b013e31828a2bbd,PELOD-2,Leteurtre,2013,1
10.1001/jama.1996.03540100046027,The Logistic Organ Dysfunction System,Le Gall,2011,1
10.1097/ccm.0b013e3181968e44,Piperacillin penetration into tissue of critically ill patients with sepsis—Bolus versus continuous administration?,Roberts,2009,1
10.1128/aac.14.6.829,Piperacillin: Human Pharmacokinetics After Intravenous and Intramuscular Administration,Tjandramaga,2012,1
10.1124/jpet.103.060137,Developmental Expression of Human Hepatic CYP2C9 and CYP2C19,Koukouritaki,2004,1
10.1177/0091270005280583,Meropenem and Continuous Renal Replacement Therapy: In Vitro Permeability of 2 Continuous Renal Replacement Therapy Membranes and Influence of Patient Renal Function on the Pharmacokinetics in Critically Ill Patients,Isla,2005,1
10.1093/jac/24.suppl_a.311,The pharmacokinetics of meropenem in volunteers,Bax,2012,1
10.1111/j.1600-0773.1973.tb01461.x,Mental and Psychomotor Effects of Diazepam and Ethanol,Haffner,2010,1
10.1080/00223980.1936.9917469,An Experimental Analysis of Incentive and Forced Application and Their Effect Upon Learning,Waskom,2010,1
10.1037/h0075814,Learning and stability: a psychophysiological analysis of a case of motor learning with clinical applications.,Snoddy,2006,1
10.1007/bf01061469,Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects,Mandema,2005,1
10.1515/9781400874668,Adaptive Control Processes,Bellman,2016,1
10.1016/j.addr.2004.07.005,The structure of the choroid plexus and the physiology of the choroid plexus epithelium,REDZIC,2004,1
10.1086/431676,The Efficacy and Safety of Tigecycline for the Treatment of Complicated Intra‐Abdominal Infections: Analysis of Pooled Clinical Trial Data,Babinchak,2005,1
10.2174/138920111798808428,Relevance of Pharmacokinetic and Pharmacodynamic Modeling to Clinical Care of Critically Ill Patients,B. Bulitta,2011,1
10.1126/science.147.3659.753,Micropuncture Study of Inulin Absorption in the Rat Kidney,Gutman,2006,1
10.1152/ajplegacy.1956.185.2.430,Micropuncture Study of Pressures in Proximal Tubules and Peritubular Capillaries of the Rat Kidney and Their Relation to Ureteral and Renal Venous Pressures,Gottschalk,2017,1
10.1007/s00134-006-0421-1,Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients,Conil,2006,1
10.1159/000057663,Comparative Pharmacokinetic and Pharmacodynamic Profile of Piperacillin/Tazobactam 3.375G Q4H and 4.5G Q6H,Mattoes,2003,1
10.1592/phco.24.6.564.34743,Tobramycin Pharmacokinetics in Children with Febrile Neutropenia Undergoing Stem Cell Transplantation: Once-Daily versus Thrice-Daily Administration,Dupuis,2004,1
10.1093/jac/39.6.677,Once-daily dosing of aminoglycosides: review and recommendations for clinical practice,Freeman,2002,1
10.1016/j.jchromb.2012.09.016,A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection,Briscoe,2012,1
10.1001/jamapediatrics.2013.196,Less Is More,Tamma,2013,1
10.1128/aac.49.1.220-229.2005,Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects,Muralidharan,2004,1
10.1016/s0924-8579(00)00198-9,In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis,Roblin,2002,1
10.1097/00006454-199506000-00002,Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia,BLOCK,2006,1
10.1017/s0195941700059774,Hospital-Acquired Infections in Intensive Care Unit Patients An Overview with Emphasis on Epidemics,Wenzel,2016,1
10.1001/jama.1977.03270520037018,Nosocomial Bacteremia,McGowan,2011,1
10.1097/00005382-198807000-00008,Lung clearance of 99mTc-DTPA in patients with acute lung injury and pulmonary edema,Coates,2006,1
10.1002/jmor.1051200305,"The transport of3H-l-histidine through the Schwann and myelin sheath into the axon, including a reevaluation of myelin function",Singer,2005,1
10.1016/0014-4886(65)90067-1,Uptake of C14-L-Lysine into segments of normal rat sciatic nerve,Appeltauer,2004,1
10.2165/00003088-200443130-00005,Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections,Moise-Broder,2006,1
10.1128/aac.43.10.2473,Use of Pharmacodynamic Indices To Predict Efficacy of Combination Therapy In Vivo,Mouton,2018,1
10.1128/aac.28.2.331,"Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions",Chalkley,2012,1
10.1136/thx.2006.067595,Survey of acute renal failure in patients with cystic fibrosis in the UK,Bertenshaw,2007,1
10.1164/rccm.200812-1845pp,Cystic Fibrosis Pulmonary Guidelines,Flume,2009,1
10.1164/ajrccm/141.4_pt_1.914,Reduction of Sputum<i>Pseudomonas aeruginosa</i>Density by Antibiotics Improves Lung Function in Cystic Fibrosis More than Do Bronchodilators and Chest Physiotherapy Alone,Regelmann,2013,1
10.1542/peds.63.1.24,The Chest Roentgenogram in Cystic Fibrosis: A New Scoring System,Brasfield,2021,1
10.1542/peds.2005-0552,Seventy-Five Years of Neonatal Sepsis at Yale: 1928–2003,Bizzarro,2005,1
10.1086/501619,Bloodstream Infections in a Neonatal Intensive-Care Unit: 12 Years' Experience With an Antibiotic Control Program,Cordero,2006,1
10.1016/0195-6701(93)90128-m,Impact of ampicillin and cefuroxime on bacterial colonization and infection in patients on a neonatal intensive care unit☆,Kalenić,2004,1
10.1056/nejm197105132841904,Empiric Therapy with Carbenicillin and Gentamicin for Febrile Patients with Cancer and Granulocytopenia,Schimpff,2010,1
10.1086/379825,Adequacy of Early Empiric Antibiotic Treatment and Survival in Severe Sepsis: Experience from the MONARCS Trial,MacArthur,2004,1
10.1093/jac/36.4.681,Bacteraemia in a community and a university hospital,Elhanan,2007,1
10.1128/jb.58.4.475-490.1949,THE SLOW RECOVERY OF BACTERIA FROM THE TOXIC EFFECTS OF PENICILLIN,Eagle,2020,1
10.1128/jb.56.1.75-81.1948,The Action of Penicillin on Staphylococcus: Further Observations on the Effect of a Short Exposure,Parker,2020,1
10.1016/j.ijantimicag.2012.10.002,β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia,Hayashi,2012,1
10.1186/cc10257,Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy,Seyler,2011,1
10.1378/chest.118.1.146,The Influence of Inadequate Antimicrobial Treatment of Bloodstream Infections on Patient Outcomes in the ICU Setting,Ibrahim,2003,1
10.1093/clinids/24.supplement_1.s17,Consequences of Bacterial Resistance to Antibiotics in Medical Practice,Acar,2011,1
10.1001/archsurg.1988.01400260113014,APACHE II Score and Abdominal Sepsis,Bohnen,2011,1
10.1093/jac/dkx093,Dose optimization of piperacillin/tazobactam in critically ill children,De Cock,2017,1
10.1097/ftd.0b013e31825a4c3a,Critical Illness Is a Major Determinant of Midazolam Clearance in Children Aged 1 Month to 17 Years,Ince,2012,1
10.1093/bja/85.4.599,The role of albumin in critical illness,Nicholson,2002,1
10.1159/000413163,Effect of Plasma and Interstitial Protein Content on Tissue Edema Formation,Demling,2015,1
10.7326/0003-4819-72-6-857,Adverse Effects of Sodium Colistimethate,KOCH-WESER,2013,1
10.1097/00003246-198608000-00028,APACHE II-A Severity of Disease Classification System,Knaus,2006,1
10.1042/bj0430169,"A study of the behaviour of some sixty amino-acids and other ninhydrin-reacting substances on phenol-‘collidine’ filter-paper chromatograms, with notes as to the occurrence of some of them in biological fluids",Dent,2015,1
10.1186/cc10441,Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams,Gonçalves-Pereira,2011,1
10.1097/00003246-200207000-00013,Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis,Joukhadar,2003,1
10.1002/(sici)1522-2683(20000501)21:8<1558::aid-elps1558>3.0.co;2-n,Micellar electrokinetic chromatography for the analysis of cefpirome in microdialysis and plasma samples obtainedin vivo from human volunteers,Mayer,2002,1
10.1002/elps.1150191616,Characterization of partitioning behavior of cephalosporins using microemulsion and micellar electrokinetic chromatography,Mrestani,2005,1
10.1023/a:1016051917608,,Schwarz,2002,1
10.1128/aac.00903-09,"Pharmacokinetic/Pharmacodynamic Investigation of Colistin against
            <i>Pseudomonas aeruginosa</i>
            Using an
            <i>In Vitro</i>
            Model",Bergen,2010,1
10.1016/j.idc.2009.06.008,Pharmacokinetics and Pharmacodynamics of Antibacterial Agents,Levison,2009,1
10.1001/archinte.1951.03810100073006,TREATMENT OF PNEUMOCOCCIC MENINGITIS WITH PENICILLIN COMPARED WITH PENICILLIN PLUS AUREOMYCIN,LEPPER,2011,1
10.1021/ci000135o,A Novel Formalism To Characterize the Degree of Unsaturation of Organic Molecules,Badertscher,2002,1
10.1021/ci950152r,"Recent Advances in the Automated Structure Elucidation System, CHEMICS. Utilization of Two-Dimensional NMR Spectral Information and Development of Peripheral Functions for Examination of Candidates",Funatsu,2002,1
10.1016/s0003-2670(00)84547-x,Use of the 13C-NMR chemical shift/charge density linear relationship for recognition and ranking of chemical structures,Bangov,2002,1
10.1021/ja01046a012,Origin of linearity of carbon-13 shift with charge. Calculations for the azines,Tokuhiro,2005,1
10.1097/00007691-200006000-00012,Diurnal Changes in the Pharmacokinetic Behavior of Amikacin,Bleyzac,2003,1
10.1038/clpt.1991.100,Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method,Dodge,2010,1
10.1038/ja.2015.127,Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii,Tran,2015,1
10.1128/aac.00865-13,Unique Structural Modifications Are Present in the Lipopolysaccharide from Colistin-Resistant Strains of Acinetobacter baumannii,Pelletier,2013,1
10.1006/abio.1994.1141,Detailed Structural Characterization of Lipid A: Electrospray Ionization Coupled with Tandem Mass-Spectrometry,Chan,2002,1
10.1016/0002-9343(91)90366-6,Epidemiology and control of nosocomial infections in adult intensive care units,Weinstein,2004,1
10.1093/infdis/152.4.769,Occult Aminoglycoside Resistance in Pseudomonas aeruginosa: Epidemiology and Implications for Therapy and Control,Olson,2011,1
10.1097/qco.0000000000000206,Optimizing dosing of antibiotics in critically ill patients,Parker,2015,1
10.1186/cc13134,Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis,Chant,2013,1
10.1016/j.ijid.2011.06.006,"Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK",Das,2011,1
10.1097/01.md.0000091182.93122.8e,Candidemia in a Tertiary Care Cancer Center,Antoniadou,2003,1
10.1128/jcm.40.4.1298-1302.2002,Epidemiology of Candidemia: 3-Year Results from the Emerging Infections and the Epidemiology of Iowa Organisms Study,Diekema,2002,1
10.1086/520194,National Epidemiology of Mycoses Survey (NEMIS): Variations in Rates of Bloodstream Infections Due to Candida Species in Seven Surgical Intensive Care Units and Six Neonatal Intensive Care Units,Rangel‐Frausto,2007,1
10.1016/s0022-3476(96)70191-9,Late-onset sepsis in very low birth weight neonates: A report from the National Institute of Child Health and Human Development Neonatal Research Network,Stoll,2006,1
10.1016/s1359-6446(97)01099-4,Managing the drug discovery/development interface,Kennedy,2002,1
10.1056/nejm199407073310103,Long-Term Risk of Breast Cancer in Women with Fibroadenoma,Dupont,2002,1
10.1002/ijc.2910470513,Benign breast disease and breast cancer: A case-control study in a cohort in italy,Palli,2007,1
10.1093/oxfordjournals.aje.a114594,"BREAST CANCER RISK ASSOCIATED WITH PROLIFERATIVE DISEASE, AGE AT FIRST BIRTH, AND A FAMILY HISTORY OF BREAST CANCER1",DUPONT,2017,1
10.1128/aac.00951-13,Protein Binding of β-Lactam Antibiotics in Critically Ill Patients: Can We Successfully Predict Unbound Concentrations?,Wong,2013,1
